- Group sales grew 7% at constant exchange rates, reaching CHF 61.5 billion in 2025.
- Pharmaceuticals Division sales rose 9%, driven by Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo.
- Diagnostics Division sales increased 2%, offsetting healthcare pricing reforms in China.
- Ten key molecules advanced to phase III development in 2025.
Financial Performance
In 2025, Roche achieved a 7% sales growth at constant exchange rates, totaling CHF 61.5 billion. The Pharmaceuticals Division saw a 9% increase, driven by key products like Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo. The Diagnostics Division grew by 2%, overcoming challenges from healthcare pricing reforms in China. Core operating profit rose by 13%, and core earnings per share increased by 11%.
Key Approvals and Developments
Roche received US and EU approval for the subcutaneous form of Lunsumio for blood cancer and EU approval for Gazyva/Gazyvaro for lupus nephritis. Positive data emerged for therapies including giredestrant for breast cancer and fenebrutinib for multiple sclerosis. Ten key molecules advanced to phase III development in 2025.
Diagnostic Innovations
Roche obtained the EU CE mark for the Elecsys Dengue Ag test and the cobas BV/CV assay, enhancing diagnostic accuracy. A CE mark was also granted for a test to monitor antibiotic therapies, expanding the automated mass spectrometry platform to 39 tests.
Board Changes and Outlook
The Board proposes Lubomira Rochet for election as a new member, while Dr. Claudia Suessmuth Dyckerhoff will not seek re-election in 2026. For 2026, Roche anticipates mid single-digit sales growth and high single-digit core earnings per share growth at constant exchange rates, with plans to further increase its dividend.
